Health Condition 1: J168- Pneumonia due to other specified infectious organisms
Conditions
Interventions
Intervention1: Aerosolized Colistin: Dose : 4 MU (diluted in 4ml sterile normal saline 0.9%).
Route of administration- Nebulization.
Nebulization will be given via an ultrasonic nebulizer . Each nebu
Sponsors
All India Institute Of Medical SciencesNew Delhi
Eligibility
Inclusion criteria
Inclusion criteria: 1)Hospitalized adults, aged = 18 years 2)Microbiologically documented VAP due to A. baumannii with carbapenem resistant strains but susceptible to Polymyxin.
Exclusion criteria
Exclusion criteria: 1)Patients’ refusal 2)Known allergies or sensitivities to nebulized colistin. 3)Pregnancy 4)Patients not expected to survive beyond 48h.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome of this study is to evaluate the clinical response in two groups after 14 days of antibiotic therapy (IV alone versus IV and aerosolized antibiotics )for Carbapenem Resistant Acinetobacter baumanii Ventilator Associated Pneumonia.Timepoint: Day 14 from start of antibiotic regimen | — |
Secondary
| Measure | Time frame |
|---|---|
| 1)Microbiological outcome at day 7 & day 14 2)Liberation from MV at day 28 3)ICU mortality 4)Hospital mortality 5)28- day mortality 6)Incidence of new onset or worsening AKI 7)Incidence of bronchospasm during nebulization Timepoint: Day 7 & Day 14 from start of antibiotic regimen | — |
Countries
India
Contacts
Public ContactAshwini A Kundar
Aiims
Outcome results
None listed